Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Hultman’s career ended in 2016, after developing the muscular disease myasthenia gravis one year earlier. Hultman dominated ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

Argenx (ARGX) announced that the U.S. Food and Drug Administration approved a new option for patients to self-inject VYVGART Hytrulo with a ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...